Anti-Lewis-Y (clone BR 96)-mc-Dox ADC (CAT#: ADC-005LZY)

This ADC product is composed of an anti-Lewis-Y antibody (clone BR 96) conjugated via mc linker to Dox (BR 96-mc-Dox). It has demonstrated a response in Lewis-Y positive tumor treatment by a MOA (Mechanism of Action) of inhibiting Topoisomerase II and causing DNA damage.


Specific Inquiry
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Normal Tissue
RNA Expression

Specifications

  • Antibody Overview
  • Chimeric anti Lewis-Y mAb,BR 96
  • Clone
  • BR 96
  • Linker
  • mc (maleimidocaproyl)
  • Linker Class/Description
  • Class: Noncleavable linker
    Description: Noncleavable linker is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation
  • Drug
  • Doxorubicin
  • Drug Class/Description
  • Class: Doxorubicin
    Description: Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

Target

  • Introduction
  • The Lewis histo-blood group system comprises a set of fucosylated glycosphingolipids that are synthesized by exocrine epithelial cells and circulate in body fluids. The glycosphingolipids function in embryogenesis, tissue differentiation, tumor metastasis, inflammation, and bacterial adhesion. They are secondarily absorbed to red blood cells giving rise to their Lewis phenotype. This gene is a member of the fucosyltransferase family, which catalyzes the addition of fucose to precursor polysaccharides in the last step of Lewis antigen biosynthesis. It encodes an enzyme with alpha(1,3)-fucosyltransferase and alpha(1,4)-fucosyltransferase activities. Mutations in this gene are responsible for the majority of Lewis antigen-negative phenotypes. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008]
  • Alternative Names
  • FUT3; fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group); LE; Les; FT3B; CD174; FucT-III; galactoside 3(4)-L-fucosyltransferase; Lewis FT; fucosyltransferase III; alpha-(1,3/1,4)-fucosyltransferase; blood group Lewis alpha-4-fucosyltransferase;

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "FUT3"

Immunotoxin

CAT Product Name Application Type
AGTO-L017E anti-FUT3 immunotoxin BR96 (IgG)-PE Cytotoxicity assay, Functional assay
AGTO-L017R anti-FUT3 immunotoxin BR96 (IgG)-RTA Cytotoxicity assay, Functional assay
AGTO-L055E anti-FUT3 immunotoxin BR96 (scFv)-PE Cytotoxicity assay, Functional assay
AGTO-L055R anti-FUT3 immunotoxin BR96 (scFv)-RTA Cytotoxicity assay, Functional assay

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for ADC-005LZY. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare